The effects of CYP2C9 and CYP2C19 genetic polymorphisms on the pharmacokinetics and pharmacodynamics of glipizide in Chinese subjects

被引：0
|
作者：
Bo Tan
Yi-Fan Zhang
Xiao-Yan Chen
Xiao-Hua Zhao
Guo-Xin Li
Da-Fang Zhong
机构：
[1] Chinese Academy of Sciences,Shanghai Institute of Materia Medica
[2] Liaoning University of Traditional Chinese Medicine,Departmant of Clinical Pharmacology, The Second Affiliated Hospital
来源：
European Journal of Clinical Pharmacology | 2010年 / 66卷
关键词：
Glipizide; Genetic polymorphism; Pharmacokinetics; Pharmacodynamics;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：145 / 151
页数：6
相关论文
共 50 条
  • [1] The effects of CYP2C9 and CYP2C19 genetic polymorphisms on the pharmacokinetics and pharmacodynamics of glipizide in Chinese subjects
    Tan, Bo
    Zhang, Yi-Fan
    Chen, Xiao-Yan
    Zhao, Xiao-Hua
    Li, Guo-Xin
    Zhong, Da-Fang
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2010, 66 (02) : 145 - 151
  • [2] Effects of CYP2C9 and CYP2C19 genetic polymorphisms on the pharmacokinetics and pharmacodynamics of gliclazide in healthy subjects
    Kang, Pureum
    Cho, Chang-Keun
    Jang, Choon-Gon
    Lee, Seok-Yong
    Lee, Yun Jeong
    Choi, Chang-Ik
    Bae, Jung-Woo
    ARCHIVES OF PHARMACAL RESEARCH, 2023, 46 (05) : 438 - 447
  • [3] Effects of CYP2C9 and CYP2C19 genetic polymorphisms on the pharmacokinetics and pharmacodynamics of gliclazide in healthy subjects
    Pureum Kang
    Chang-Keun Cho
    Choon-Gon Jang
    Seok-Yong Lee
    Yun Jeong Lee
    Chang-Ik Choi
    Jung-Woo Bae
    Archives of Pharmacal Research, 2023, 46 : 438 - 447
  • [4] CYP2C9, but not CYP2C19, polymorphisms affect the pharmacokinetics and pharmacodynamics of glyburide in Chinese subjects
    Yin, OQP
    Tomlinson, B
    Chow, MSS
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2005, 78 (04) : 370 - 377
  • [5] Impacts of CYP2C9 and CYP2C19 genetic polymorphisms on pharmacokinetics of gliclazide in Chinese subjects
    Zhang, Yifan
    Chen, Xiaoyan
    Lin, Nan
    Zhong, Dafang
    Si, Dayong
    Gu, Yingjie
    Zhou, Hui
    DRUG METABOLISM REVIEWS, 2006, 38 : 161 - 162
  • [6] Influence of CYP2C9 and CYP2C19 genetic polymorphisms on pharmacokinetics of gliclazide MR in Chinese subjects
    Zhang, Yifan
    Si, Dayong
    Chen, Xiaoyan
    Lin, Nan
    Guo, Yingjie
    Zhou, Hui
    Zhong, Dafang
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2007, 64 (01) : 67 - 74
  • [7] Effects of CYP2C9 and CYP2C19 polymorphisms on the pharmacokinetics and pharmacodynamics of gliclazide in healthy Korean subjects.
    Choi, C.
    Bae, J.
    Kim, M.
    Jang, C.
    Lee, S.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2008, 83 : S68 - S68
  • [8] Influence of CYP2C9 and CYP2C19 genetic polymorphisms on pharmacokinetics and pharmacodynamics of gliclazide in healthy Chinese Han volunteers
    Shao, H.
    Ren, X. M.
    Liu, N. F.
    Chen, G. M.
    Li, W. L.
    Zhai, Z. H.
    Wang, D. W.
    JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS, 2010, 35 (03) : 351 - 360
  • [9] Impact of Genetic Polymorphisms in CYP2C9 and CYP2C19 on the Pharmacokinetics of Clinically Used Drugs
    Hirota, Takeshi
    Eguchi, Shunsuke
    Ieiri, Ichiro
    DRUG METABOLISM AND PHARMACOKINETICS, 2013, 28 (01) : 28 - 37
  • [10] Effects of polymorphisms in CYP2D6, CYP2C9, and CYP2C19 on trimipramine pharmacokinetics
    Kirchheiner, J
    Müller, G
    Meineke, I
    Wernecke, KD
    Roots, I
    Brockmöller, J
    JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, 2003, 23 (05) : 459 - 466
12345